Passage Bio’s CEO Option Grant Signals Strategic Turnaround for Investors
Passage Bio’s new CEO stock‑option grant signals a strategic reset, balancing insider confidence with shareholder risk while pushing clinical milestones, reimbursement wins, and tech‑driven trials to unlock upside potential.
4 minutes to read